Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions

Gerhard Bauer, Magdi Elsallab, Mohamed Abou-El-Enein

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

The promise of stem cell (SC) therapies to restore functions of damaged tissues and organs brings enormous hope to patients, their families, loved ones, and caregivers. However, limits may exist for which indications SC therapies might be useful, efficacious, and safe. Applications of innovative therapies within regulatory boundaries and within the framework of controlled clinical trials are the norm in the scientific and medical community; such a system minimizes patient risk by setting a clear and acceptable safety and efficacy profile for new therapeutics before marketing authorization. This careful clinical validation approach often takes time, which patients suffering from terminal or debilitating diseases do not have. Not validated, unproven stem cell interventions (SCI) that promise a working treatment or cure for severe diseases have therefore found their way into the patient community, and providers of such treatments often take advantage of the public's willingness to pay large amounts of money for the misguided hope of a reliable recovery from their illnesses. We conducted a review of scientific publications, clinical case reports, and mass media publications to assess the reported cases and safety incidents associated with unproven SCI. The review also analyzes the main factors that were identified as contributing to the emergence and global rise of the “stem cell tourism” phenomenon. Stem Cells Translational Medicine 2018;1–10.

Original languageEnglish (US)
Pages (from-to)676-685
Number of pages10
JournalStem cells translational medicine
Volume7
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Stem Cells
Hope
Cell- and Tissue-Based Therapy
Publications
Safety
Mass Media
Investigational Therapies
Translational Medical Research
Controlled Clinical Trials
Marketing
Caregivers
Statistical Factor Analysis
Therapeutics

Keywords

  • Adverse events
  • Clinical trials
  • Ethics
  • Hype
  • Mesenchymal stromal cells
  • Regulations
  • Risks
  • Stem cell clinics
  • Stem cell tourism
  • Stem cells
  • Unproven interventions

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Cite this

Concise Review : A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. / Bauer, Gerhard; Elsallab, Magdi; Abou-El-Enein, Mohamed.

In: Stem cells translational medicine, Vol. 7, No. 9, 01.09.2018, p. 676-685.

Research output: Contribution to journalReview article

@article{3754315c72d14ee2a294002d1d084f6a,
title = "Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions",
abstract = "The promise of stem cell (SC) therapies to restore functions of damaged tissues and organs brings enormous hope to patients, their families, loved ones, and caregivers. However, limits may exist for which indications SC therapies might be useful, efficacious, and safe. Applications of innovative therapies within regulatory boundaries and within the framework of controlled clinical trials are the norm in the scientific and medical community; such a system minimizes patient risk by setting a clear and acceptable safety and efficacy profile for new therapeutics before marketing authorization. This careful clinical validation approach often takes time, which patients suffering from terminal or debilitating diseases do not have. Not validated, unproven stem cell interventions (SCI) that promise a working treatment or cure for severe diseases have therefore found their way into the patient community, and providers of such treatments often take advantage of the public's willingness to pay large amounts of money for the misguided hope of a reliable recovery from their illnesses. We conducted a review of scientific publications, clinical case reports, and mass media publications to assess the reported cases and safety incidents associated with unproven SCI. The review also analyzes the main factors that were identified as contributing to the emergence and global rise of the “stem cell tourism” phenomenon. Stem Cells Translational Medicine 2018;1–10.",
keywords = "Adverse events, Clinical trials, Ethics, Hype, Mesenchymal stromal cells, Regulations, Risks, Stem cell clinics, Stem cell tourism, Stem cells, Unproven interventions",
author = "Gerhard Bauer and Magdi Elsallab and Mohamed Abou-El-Enein",
year = "2018",
month = "9",
day = "1",
doi = "10.1002/sctm.17-0282",
language = "English (US)",
volume = "7",
pages = "676--685",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "9",

}

TY - JOUR

T1 - Concise Review

T2 - A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions

AU - Bauer, Gerhard

AU - Elsallab, Magdi

AU - Abou-El-Enein, Mohamed

PY - 2018/9/1

Y1 - 2018/9/1

N2 - The promise of stem cell (SC) therapies to restore functions of damaged tissues and organs brings enormous hope to patients, their families, loved ones, and caregivers. However, limits may exist for which indications SC therapies might be useful, efficacious, and safe. Applications of innovative therapies within regulatory boundaries and within the framework of controlled clinical trials are the norm in the scientific and medical community; such a system minimizes patient risk by setting a clear and acceptable safety and efficacy profile for new therapeutics before marketing authorization. This careful clinical validation approach often takes time, which patients suffering from terminal or debilitating diseases do not have. Not validated, unproven stem cell interventions (SCI) that promise a working treatment or cure for severe diseases have therefore found their way into the patient community, and providers of such treatments often take advantage of the public's willingness to pay large amounts of money for the misguided hope of a reliable recovery from their illnesses. We conducted a review of scientific publications, clinical case reports, and mass media publications to assess the reported cases and safety incidents associated with unproven SCI. The review also analyzes the main factors that were identified as contributing to the emergence and global rise of the “stem cell tourism” phenomenon. Stem Cells Translational Medicine 2018;1–10.

AB - The promise of stem cell (SC) therapies to restore functions of damaged tissues and organs brings enormous hope to patients, their families, loved ones, and caregivers. However, limits may exist for which indications SC therapies might be useful, efficacious, and safe. Applications of innovative therapies within regulatory boundaries and within the framework of controlled clinical trials are the norm in the scientific and medical community; such a system minimizes patient risk by setting a clear and acceptable safety and efficacy profile for new therapeutics before marketing authorization. This careful clinical validation approach often takes time, which patients suffering from terminal or debilitating diseases do not have. Not validated, unproven stem cell interventions (SCI) that promise a working treatment or cure for severe diseases have therefore found their way into the patient community, and providers of such treatments often take advantage of the public's willingness to pay large amounts of money for the misguided hope of a reliable recovery from their illnesses. We conducted a review of scientific publications, clinical case reports, and mass media publications to assess the reported cases and safety incidents associated with unproven SCI. The review also analyzes the main factors that were identified as contributing to the emergence and global rise of the “stem cell tourism” phenomenon. Stem Cells Translational Medicine 2018;1–10.

KW - Adverse events

KW - Clinical trials

KW - Ethics

KW - Hype

KW - Mesenchymal stromal cells

KW - Regulations

KW - Risks

KW - Stem cell clinics

KW - Stem cell tourism

KW - Stem cells

KW - Unproven interventions

UR - http://www.scopus.com/inward/record.url?scp=85052795693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052795693&partnerID=8YFLogxK

U2 - 10.1002/sctm.17-0282

DO - 10.1002/sctm.17-0282

M3 - Review article

C2 - 30063299

AN - SCOPUS:85052795693

VL - 7

SP - 676

EP - 685

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 9

ER -